Navigation Links
Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
Date:12/14/2010

PARSIPPANY, N.J., Dec. 14, 2010 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, announced today that the New Drug Application (NDA) for EXPAREL™, a long-acting bupivacaine for postsurgical pain management, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Pacira submitted the EXPAREL NDA in September 2010 for the initial indication of postsurgical analgesia by local administration. The FDA also notified Pacira that its Prescription Drug User Fee Act (PDUFA) target date (the date the FDA expects to complete its review of the EXPAREL NDA) is July 28, 2011.  

About PaciraPacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, commercialization and manufacture of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. The company's most advanced product candidate, EXPAREL, a bupivacaine-based product, has completed Phase 3 clinical development for postoperative analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.ContactJames S. Scibetta, CFO, Pacira Pharmaceuticals, Inc.973-254-3560
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
4. ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
5. Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
6. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
7. Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
8. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
9. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
10. Access Pharmaceuticals Reports Significant Third Party Payer Reimbursement Progress for MuGard
11. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 21, 2017 , ... Contrary to popular perception, a new ... at noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found a ... the United States. The study, Trends in Fighting and Violence Among Adolescents ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Brady ... that its B-595 and B-7569 vinyl label materials received certification ... warning labels are tested to remain intact and legible, for use on chemical drums ...
(Date:4/21/2017)... Colo. (PRWEB) , ... April 21, 2017 , ... The ... the Flex House, the next project in the company’s esteemed VISION House demonstration project ... homeowners use exactly the amount of resources they need to live affordably and abundantly ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The Hong ... the first 3D printing facility among higher education institutions in Hong Kong to support ... in terms of the range and quantity of facilities in Hong Kong. , ...
(Date:4/21/2017)... British Columbia (PRWEB) , ... April 21, 2017 , ... ... at treating people who wish to overcome their mental health struggles. The Alive team ... Director Vic LeBouthillier says: “Our approach in dealing with a mental health struggle is ...
Breaking Medicine News(10 mins):